...
首页> 外文期刊>Molecular pharmaceutics >Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
【24h】

Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.

机译:雌激素锚定的pH敏感脂质体作为纳米模块,设计用于乳腺癌治疗中阿霉素的部位特异性递送。

获取原文
获取原文并翻译 | 示例

摘要

The present investigation reports the development of nanoengineered estrogen receptor (ER) targeted pH-sensitive liposome for the site-specific intracellular delivery of doxorubicin (DOX) for breast cancer therapy. Estrone, a bioligand, was anchored on the surface of pH-sensitive liposome for drug targeting to ERs. The estrone-anchored pH-sensitive liposomes (ES-pH-sensitive-SL) showed fusogenic potential at acidic pH (5.5). In vitro cytotoxicity studies carried out on ER-positive MCF-7 breast carcinoma cells revealed that ES-pH-sensitive-SL formulation was more cytotoxic than non-pH-sensitive targeted liposomes (ES-SL). The flow cytometry analysis confirmed significant enhanced uptake (p < 0.05) of ES-pH-sensitive-SL by MCF-7 cells. Intracellular delivery and nuclear localization of the DOX was confirmed by fluorescence microscopy. The mechanism for higher cytotoxicity shown by estrone-anchored pH-sensitive liposomal-DOX was elucidated using reactive oxygen species (ROS) determination. The in vivo biodistribution studies and antitumor activities of formulations were evaluated on tumor bearing female Balb/c mice followed by intravenous administration. The ES-pH-sensitive-SL efficiently suppressed the breast tumor growth in comparison to both ES-SL and free DOX. Serum enzyme activities such as LDH and CPK levels were assayed for the evaluation of DOX induced cardiotoxicity. The ES-pH-sensitive-SL accelerated the intracellular trafficking of encapsulated DOX, thus increasing the therapeutic efficacy. The findings support that estrone-anchored pH-sensitive liposomes could be one of the promising nanocarriers for the targeted intracellular delivery of anticancer agents to breast cancer with reduced systemic side effects.
机译:本研究报告了针对乳腺癌治疗的阿霉素(DOX)的位点特异性细胞内递送的针对纳米工程化雌激素受体(ER)的pH敏感脂质体的开发。雌激素,一种生物配体,锚定在pH敏感脂质体的表面上,用于靶向ERs的药物。雌酮固定的pH敏感脂质体(ES-pH敏感SL)在酸性pH(5.5)时具有融合潜力。在ER阳性MCF-7乳腺癌细胞上进行的体外细胞毒性研究显示,ES-pH敏感性SL制剂比非pH敏感性靶向脂质体(ES-SL)更具细胞毒性。流式细胞仪分析证实MCF-7细胞可显着提高ES-pH敏感SL的摄取(p <0.05)。通过荧光显微镜确认了DOX的细胞内递送和核定位。使用活性氧(ROS)测定阐明了雌酮固定的pH敏感脂质体-DOX所显示的更高的细胞毒性机制。在荷瘤雌性Balb / c小鼠上评估制剂的体内生物分布研究和抗肿瘤活性,然后静脉内给药。与ES-SL和游离DOX相比,ES-pH敏感型SL可有效抑制乳腺肿瘤的生长。测定血清酶活性,如LDH和CPK水平,以评估DOX诱导的心脏毒性。 ES-pH敏感的SL加速了封装的DOX的细胞内运输,从而提高了治疗效果。这些发现支持了雌酮锚定的pH敏感脂质体可能是有希望的纳米载体之一,可将抗癌剂靶向性细胞内递送至乳腺癌,降低系统性副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号